"We expected to see a significant improvement in outcomes for patients with severe or rapidly progressing cardiogenic shock who underwent early ECMO treatment," one specialist said. 

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

“The findings of this study are important because they provide fresh evidence that the use of e-cigarettes could interfere with normal heart rhythms—something we did not know before,” according to one specialist. 

Researchers tracked outcomes data and imaging results from nearly 4,000 TEER patients, sharing their findings in the Journal of the American College of Cardiology.

“Because patients with aortic stenosis are old and commonly have chronic kidney disease, it is essential to evaluate the renal function before TAVR," the study's authors wrote. “Albuminuria indicates glomerular injury and is an important factor in the assessment of renal function or diagnosis of chronic kidney disease."

Reviewing data from more than 23.5 million U.S. patients, the study's authors found that methamphetamine use was linked to a whopping 86% increase in a patient's AFib risk. The other substances included in the analysis were not far behind. 

Researchers examined data from patients who underwent high-risk PCI with either an Impella heart pump or an intra-aortic balloon pump.